PBL gains approval to advance next generation anthrax vaccine

Porton Biopharma Ltd (PBL) has today announced that it has signed a modification to its contract with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases (NIAID) to advance a next generation intra-nasal anthrax vaccine. The contract modification is worth US$5.6 million.

read more

PBL Opens Quality Accommodation

quality office accomodation

We have opened a brand new suite of office accommodation that will bring together members of Quality Assurance (QA) and other departments into one integrated set of buildings, which will both improve efficiency and also demonstrates the investment that we are making in the company.

read more

Erwinase® gains Marketing Approval in Japan

Porton Biopharma Limited has been working to support Ohara Pharmaceutical Co. Ltd. who have today announced that they have obtained marketing approval for Erwinase® from the Ministry of Health Labour and Welfare in Japan.

read more

New Finance Director Joins PBL

Amir Malik

PBL have appointed Amir Malik as finance director to assist with strategic planning and direction.  Amir has almost 20 years experience in a range of strategic finance roles, is a qualified chartered accountant, has an MBA in finance and  a BSc in Chemistry, and brings a wealth of experience of working in both the public and private sectors

read more

Porton Biopharma investing in staff

Our latest cohort of staff have been independently assessed and achieved a whole series of level 2 and 3 NVQ awards, the awards are in subjects including storage & warehousing and laboratory skills.

read more

Porton Biopharma appoints new Non Executive Director

We are pleased to announce that we have appointed Nigel Brooksby as a new Non Executive Director to the PBL Board.  Nigel will take up his position from June and brings to the Board his considerable knowledge and experience in biopharmaceuticals and life-sciences.

read more